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Dysfunctional Epstein-Barr virus (EBV)–specific CD81 T lymphocytes and
increased EBV load in HIV-1 infected individuals progressing
to AIDS-related non-Hodgkin lymphoma
Debbie van Baarle, Egbert Hovenkamp, Margareth F. C. Callan, Katja C. Wolthers, Stefan Kostense, Linda C. Tan,
Hubert G. M. Niesters, Albert D. M. E. Osterhaus, Andrew J. McMichael, Marinus H. J. van Oers, and Frank Miedema
Acquired immunodeficiency syndrome–
related non-Hodgkin lymphomas (AIDS-
NHL) are thought to arise because of loss
of Epstein-Barr Virus (EBV)-specific cellu-
lar immunity. Here, an investigation was
done to determine whether cellular immu-
nity to EBV is lost because of physical
loss or dysfunction of EBV-specific cyto-
toxic T cells. Data on EBV-specific cellu-
lar immunity were correlated with EBV
load. For comparison, individuals who
progressed to AIDS with opportunistic
infections (AIDS-OI) and long-term asymp-
tomatics (LTAs) were studied. The num-
ber of virus-specific T cells was detected
using tetrameric HLA–EBV-peptide com-
plexes; function of these EBV-specific T
cells was determined using the inter-
feron-g (IFN-g) Elispot assay. It was ob-
served that EBV-specific CD81 T cells
were present in normal numbers in hu-
man immunodeficiency virus (HIV)-in-
fected individuals. However, their func-
tional capacity was decreased compared
with HIV2 individuals. In AIDS-NHL pa-
tients, EBV-specific T cells were not physi-
cally lost in the course of HIV-1 infection
but showed progressive loss of their capa-
bility to produce IFN-g in response to
EBV peptides. This loss of function corre-
lated with lower CD41 T-cell numbers and
was accompanied by increasing EBV load.
In HIV-1–infected LTA individuals, in whom
CD41 T-cell numbers were maintained,
and progressors to AIDS-OI, IFN-g–pro-
ducing EBV-specific T cells were stable
and EBV load remained stable or de-
creased in the course of HIV infection,
suggestive of immune control. Our data
indicate that functional loss of EBV-
specific CD81 T cells with a concomitant
increase in EBV load may play a role in
the pathogenesis of AIDS-NHL. (Blood.
2001;98:146-155)
© 2001 by The American Society of Hematology
Introduction
Epstein-Barr virus (EBV) is a widespread human gamma herpesvi-
rus. Primary infection with EBV usually occurs asymptomatically,1
whereafter the virus persists for life in a latent form in B
lymphocytes.2 The initial expansion and reactivation of these
latently infected B lymphocytes is controlled by specific CD81
major histocompatibility complex (MHC) class I–restricted cyto-
toxic T-lymphocyte (CTL) responses.3 Because reactivation may
result in lytic antigen expression,4 CTL control during this stage of
reactivation may involve lytic antigen-specific effector T cells.5
During immunodeficiency, a higher rate of reactivation of EBV
infection may lead to uncontrolled lymphoproliferation.6 In human
immunodeficiency virus (HIV)-infected individuals, the incidence
of non-Hodgkin lymphomas (NHLs) is considerably increased
(5%-10%), and most of these lymphomas (75%) are EBV1.7 These
acquired immunodeficiency syndrome (AIDS)-related diffuse large
cell NHLs are therefore thought to arise because of loss of
EBV-specific T-cell immunity.8,9
Until now, only few cross-sectional studies have been per-
formed to study EBV-specific immunity in AIDS-NHL patients.
Some studies show decreased EBV-specific cytotoxic T-cell activ-
ity in patients with AIDS and AIDS-related complex.10 In contrast,
other studies by Carmichael et al and Geretti et al comparing EBV-
with HIV-specific T-cell responses showed sustained EBV-specific
CTL responses with declining HIV-1–specific CTL in advanced
HIV-1 infection, suggesting selective loss of HIV-1–specific
CTL.11,12 We previously reported a longitudinal study into the
kinetics of HIV-1– and EBV-specific CTL responses in HIV-
infected individuals using limiting dilution analysis to determine
the number of CTL precursors (CTLp). This study revealed that
loss of HIV-specific CTLs is not necessarily paralleled by loss of
EBV-specific T-cell responses. In patients with AIDS-NHL, diagno-
sis of NHL was found to be preceded by a decrease in EBV CTLp
and an increase in the number of infected B cells as measured in an
in vitro EBV transformation assay.8
The underlying cause for this loss in EBV-specific CTLp is
unknown. Recently, new techniques using MHC class I–peptide
tetrameric complexes have been developed for enumerating antigen-
specific CD81 T cells.13 This method demonstrated a much higher
frequency of antigen-specific circulating T cells than previously
estimated by limiting dilution analysis. Moreover, interferon (IFN)-g
Elispot assays have been shown to enable enumeration of func-
tional EBV-specific T cells at the peptide level.14 Combination of
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these new methods allowed us to investigate at the peptide level
whether EBV-specific CD81 T cells become either deleted or
dysfunctional in patients who have developed AIDS-NHL. In
addition, using a real-time quantitative polymerase chain reaction
(PCR) assay, EBV DNA in infected cells was quantitated. Presence
and function of CD81 T lymphocytes specific for peptides from
both latent and lytic EBV antigens were studied, and EBV load was
measured in the course of HIV-1 infection in AIDS-NHL patients.
For comparison, HIV-1–infected individuals who progressed to
AIDS with opportunistic infections (AIDS-OI) or were long-term
asymptomatic (LTA) were studied.
Patients, materials, and methods
Study population
This study was performed on participants of the Amsterdam Cohort Studies
on AIDS and HIV-1 infection. From these individuals at risk of HIV-1
infection, we selected HIV1 homosexual males according to duration of
follow-up, availability of samples, and HLA type. Blood samples from
these individuals were collected every 3 months for HIV-1 serology and
immunologic studies. In addition, at all time points peripheral blood
mononuclear cells (PBMCs) were cryopreserved.
We analyzed longitudinal PBMC samples from 5 HIV-1 infected
individuals progressing to AIDS-related diffuse large cell NHL (NHL6006,
NHL0118, NHL6118, NHL0139, NHL0308), starting at or soon after
HIV-1 seroconversion. For comparison, we studied PBMC samples from 3
HIV-1–infected individuals progressing to AIDS (classification of the
Centers for Disease Control, 1993) with opportunistic infections
(PROG0232, PROG0341, PROG0642) and 3 HIV-infected LTA (LTA0036,
LTA1160, LTA0057) individuals with CD41 T-cell counts above 500/mL
during more than 8 years of asymptomatic follow-up. Characteristics of the
HIV-1–infected individuals are summarized in Table 1. In addition, PBMC
samples from 6 HIV2 individuals who were either HLA-B81 or HLA-
A21B81 were analyzed. Approval for these studies was obtained from the
Academic Medical Center Institutional Review Board. Informed consent
was provided according to the Declaration of Helsinki.
Flow cytometry and tetramer staining
MHC class I tetramers complexed with EBV peptides were produced as
previously described.13 The peptides used (synthesized by solid-phase
methods using an automated multiple-peptide synthesizer and Fmoc
chemistry) were 2 immunodominant epitopes from EBV lytic cycle
proteins, the HLA-A2–restricted epitope GLCTLVAML (A2-GLC) from
BMLF-115 and the HLA-B8–restricted epitope RAKFKQLL (B8-RAK)
from BZLF-1,16 and 1 immunodominant epitope from the latent antigen
EBNA-3A, the HLA-B8–restricted epitope FLRGRAYGL (B8-FLR).17
Biotinylated class I peptide complexes were tetramerized by addition of
allophycocyanin or phycoerythrin-conjugated streptavidin.
Two-color fluorescence analysis was performed as previously de-
scribed.18 Briefly, PBMCs were thawed, and 1.5 3 106 cells were stained in
phosphate-buffered saline (PBS) supplemented with 0.5% (vol/vol) bovine
serum albumin (BSA) with MHC class I tetramers and peridinin chloro-
phyll protein (PerCP)-conjugated monoclonal antibody (mAb) CD8 (Bec-
ton Dickinson, San Jose, CA). After staining, cells were washed with
PBS/BSA and fixed in PBS/1% paraformaldehyde, and at least 250 000
events were acquired using a FACSCalibur flow cytometer (Becton
Dickinson). The tetramer staining was very reproducible because multiple
stainings on PBMCs from the same donor gave similar results.
To determine the percentage of dead cells in each sample, a propidium
iodide staining was performed. Lymphocytes were gated by forward and
side scatter. Data were analyzed using the software program Cell Quest
(Becton Dickinson).
T-lymphocyte immunophenotyping for CD4 and CD8 membrane
markers was performed in real time by flow cytometry.
Elispot assay for single-cell IFN-g release
IFN-g–producing antigen-specific T cells were enumerated using IFN-g–
specific Elispot assays as previously described.14 A total of 96-well
nylon-backed plates (Nunc, Roskilde, Denmark) were coated overnight
with 50 mL of 15 mg/mL anti–IFN-g mAb, 1-DIK (Mabtech, Stockholm,
Sweden), in 0.1 M carbonate/bicarbonate buffer, pH 9.6. After 6 wash steps
with culture medium (RPMI 1640, Gibco, Life Technologies, Breda, The
Netherlands) to remove unbound antibody, plates were blocked for 1 hour
with RPMI 1640 supplemented with 10% fetal calf serum. Subsequently,
PBMCs were added in triplicate wells at 1 3 105 cells per well in case of
HLA-B8–restricted responses or 2 3 105 cells per well in case of HLA-A2–
restricted responses in the absence or presence of 2 mM peptide. As a
positive control to test the capacity of PBMCs to produce IFN-g in general,
phytohemagglutinin (Murex Diagnostics, Dartford, United Kingdom) was
added. Cultures were incubated overnight at 37°C in 5% CO2. The next day,
cells were removed by washing with PBS/0.05% Tween 20, and the second
biotinylated anti–IFN-g mAb, 7-B6-1 biotin (Mabtech), was added at 1
mg/mL in PBS and left for 3 hours at room temperature, followed by
streptavidin-conjugated alkaline phosphatase (Mabtech) for an additional 2
hours. Individual cytokine-producing cells were detected as dark purple
spots after a 10-minute reaction with 5-bromo-4-chloro-3-indolyl phos-
phate and nitroblue tetrazolium (BCIP/NBT, Sigma, St Louis, MO).
Reactions were stopped by extensive washing in water. Nylon membranes
were dried, and spots were counted after computerized visualization by a
scanner (Hewlett-Packard, Boise, ID). The number of specific T-cell
responders per 106 PBMCs were calculated after subtracting negative
control values. Because the percentage of dead cells and the percentage
of CD81 T cells were assessed in the same samples, the number of specific
T-cell responders per 106 living CD81 T cells could be calculated. This
assay was very reproducible when performed on multiple samples
from EBV1 donors, detecting as low as 1 positive cell per 1 3 105
PBMCs (0.001%).
Intracellular IFN-g staining after antigen-specific stimulation
A total of 2 3106 PBMCs per milliliter were either stimulated with 1 mg
EBV (RAK) peptide, used in the tetrameric complexes, or PMA/ionomycin
(positive control) or not stimulated (medium alone as negative control) at
37°C for 4 hours in the presence of 3 mM monensin.19 This stimulation was
sufficient to induce IFN-g production in most potential cells. Stronger
stimulation protocols (10 mg peptide per milliliter for 6 hours) did not
substantially increase the number of IFN-g–producing cells. After incuba-
tion, cells were washed and stained in PBS supplemented with 0.5%
(vol/vol) BSA for 15 minutes with HLA-B8–RAK tetramers (APC) and
Table 1. Characteristics of HIV-1–infected individuals
Participant Age* HLA class I Follow-up†
CD4
counts‡ Diagnosis
NHL0118 36 A2, 3; B51, 60 124 , 0.19 NHL
NHL0139 46 A2; B8, 51 87 , 0.06 NHL
NHL0308 34 A1; B8, 51 94 0.07 NHL
NHL6006 41 A2, 32; B7, 35 76 0.1 NHL
NHL6118 25 A2, 3: B8, 37 25 0.19 NHL
PROG0232 35 A1, 3; B7, 8 134 0.23 Mycobact
PROG0341 33 A24, 28: B8, 13 128 0.09 PCP
PROG0642 43 A3; B8, 70 39 0.04 PCP
LTA0036 44 A1, 32; B8, 44 95 0.36 —
LTA0057 39 A2, 19; B27, 40 162 0.34 —
LTA1160 35 A2; B8, 27 128 0.24 —
NHL indicates B-cell NHL; PCP, Pneumocystis carinii pneumonia; Mycobact,
Mycobacterium tuberculosis extrapulmonary.
*Age in years at HIV-1 seroconversion or first seropositive visit.
†Seropositive follow-up, in months, from HIV-1 seroconversion or first seroposi-
tive visit until AIDS diagnosis or last time point studied.
‡CD41 T-cell numbers 3 1000/mL at AIDS diagnosis or last time point studied
for LTAs.
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PerCP-conjugated mAb CD8 (Becton Dickinson). After membrane stain-
ing, cells were washed with PBS/BSA and fixed with 4% paraformalde-
hyde, permeabilized (permeabilization kit, Becton Dickinson), and stained
intracellularly with IFN-g–PE (Becton Dickinson) for 30 minutes at 4°C. At
least 200 000 events in the lymphogate were acquired using a FACSCalibur
flow cytometer (Becton Dickinson).
DNA extraction and real-time quantitative TaqMan assay
PBMCs (1 3 106) were lysed by addition of L6-lysis buffer.20 Genomic
DNA was extracted by precipitation with isopropanol, and DNA from
2 3 105 cells was amplified using PCR primers selective for the EBV DNA
genome encoding the nonglycosylated membrane protein BNRF1 p143.21,22
PCR amplification was performed as previously described23 using EBV/
p143 forward and reverse primers resulting in a 74–base pair DNA product.
In the PCR reaction, a fluorigenic EBV/p143-specific probe was added with
a FAM reported molecule attached to the 59 end and a TAMRA quencher
linked at the 39 end to detect amplified DNA. Amplification and detection
was performed with an ABI Prism 7700 Sequence Detection System (PE
Applied Biosystems, Foster City, CA). Real-time measurements were
taken, and a threshold cycle value was calculated for each sample by
determining the point at which the fluorescence exceeded a threshold limit
of 0.04. Each run contained several negative controls (no template or EBV2
DNA), a positive control (a known amount of EBV copies), and a standard
dilution of plasmid DNA containing the PCR product as insert, which was
calibrated with an EBV-quantified standard (Advanced Biotechnologies,
Epsom, United Kingdom). The analyzed sensitivity of the assay was between
50 and 5 3 106 copies per milliliter. All reactions were performed in duplicate
and only considered positive when both replications were above the
threshold limit. The variation between duplicates was as low as 7.5%.
Statistical analysis
To compare EBV-specific tetramer1 T cells, IFN-g–producing CD81 T
cells, and EBV load early and late in HIV infection, Wilcoxon tests were
performed. To compare all variables early or late between groups,
Mann-Whitney tests were performed using the software program SPSS 7.5
(SPSS, Chicago, IL). To test the relation between CD41 T-cell numbers and
EBV-specific functional CD81 T cells, EBV-tetramer1 T cells, or total
CD81 T cells, regression analyses (mixed linear model) were performed.
Regression analysis and multivariate analysis to search for predictors of the
number of functional T cells were performed after cube root transformation
of all variables. To correct for a possible correlation between multiple
observations from one person, compound symmetry was used as correlation
structure using the Proc Mixed procedure of the software program SAS.
Results
Direct visualization and functional analysis of EBV-specific
CD81 T lymphocytes
To investigate the presence and function of EBV-specific CD81 T
cells, we studied CD81 T cells specific for 2 epitopes derived from
lytic antigens, the HLA-A2–restricted epitope GLCTLVAML (A2-
GLC) and the HLA-B8–restricted epitope RAKFKQLL (B8-
RAK), and for 1 epitope derived from a latent antigen, the
HLA-B8–restricted epitope FLRGRAYGL (B8-FLR). To detect the
presence of antigen-specific CD81 T cells, we stained antigen-
specific T cells using tetrameric HLA-peptide complexes. To assess
the function of antigen-specific CD81 T cells, we used the IFN-g
Elispot assay, which shows the number of IFN-g–producing T cells
after peptide stimulation. To determine the sensitivity of both
assays, we applied them both to an HIV-specific T-cell clone that
was selected in vitro to respond to one specific (HIV RT) peptide.24
In Figure 1 (left panel), tetramer staining of this T-cell clone is
shown, revealing that 87% of the T-cell clone was specific for the
tetramer containing the specific peptide. IFN-g Elispot revealed
that virtually all tetramer1 T cells from the T-cell clone produced
IFN-g upon stimulation with the specific peptide (Figure 1A, right
panel), because almost every (93%) tetramer1 T cell could be
accounted for in the Elispot assay. In addition, IFN-g production
was similar in both Elispot assay and intracellular FACS staining
(manuscript in preparation). Tetramer staining of PBMCs from a
healthy EBV-carrying individual showed that approximately 3% of
the CD81 T cells were specific for an EBV-peptide (Figure 1B, left
panel), half of which produced IFN-g after peptide stimulation in a
direct ex vivo assay using intracellular staining (Figure 1B, right
panel) or Elispot assay (data not shown). Furthermore, both assays
were reproducible and sensitive on both fresh and frozen material
(data not shown).
In preliminary studies using IFN-g Elispot assay, the selected
EBV epitopes were shown to be immunodominant in that they were
recognized by a high frequency of CD81 T cells (100-400
peptide-specific T cells per 106 PBMCs) in all HIV-infected
individuals studied. HLA-A2–restricted latent antigen-specific T
cells were either not present or present in a very low range (data not
shown). Therefore, HLA-A2–restricted T cells against latent
epitopes were not studied.
Lower numbers of functional EBV-specific CD81 T cells in HIV1
versus HIV2 individuals
After immunodominance was established, the number and function
of EBV peptide–specific CD81 T lymphocytes was measured in
HIV2 and HIV1 individuals in the course of HIV-1 infection. For
Figure 1. Tetramer staining and IFN-g production of a T-cell clone and PBMCs.
(A) The left panel shows tetramer staining of a T-cell clone of which most of the T cells
are specific for one peptide, revealing the presence of ; 87% tetramer1 CD81 T cells
(upper right quadrant). In the right panel, a well of a 96-well nitrocellulose-backed
plate containing spots is shown, revealing ;100 IFN-g–producing T cells (;80%)
after peptide stimulation of ;125 cells of the T-cell clone, which comes down
to ;93% IFN-g–producing tetramer1 T cells. (B) Percentage tetramer staining (3.3%,
left panel) and percentage IFN-g–producing CD81 T cells after peptide (RAK)
stimulation and intracellular IFN-g staining (1.6%, right panel) of PBMCs of a healthy
EBV carrier.
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comparisons, both the total number of circulating (tetramer1 as
percentage of CD81) and the total number of functional (IFN-g–
producing as number per 106 CD81) EBV-specific CD81 T cells
was calculated from the individual peptide-specific CD81 T cells.
Combining these 2 parameters, the proportion of IFN-g1 tetramer1
T cells could be determined.
In this study population, 0.2% to 5% of the CD81 T cells were
EBV-specific. (Figure 2A). No difference in the percentage of
tetramer1 EBV-specific CD81 T cells was observed between HIV2
and HIV1 individuals early in HIV infection (P 5 .42, Mann-
Whitney test) (Figure 2A). Interestingly, in HIV2 individuals a
higher proportion of these EBV-specific T cells produced IFN-g in
response to the selected dominant EBV peptides (median 22%,
range 12%-28%) than in HIV1 individuals early in HIV infection
(median 13%, range 6%-15%) (P 5 .014, Mann-Whitney test)
(Figure 2B).
Progressive loss of function of EBV-specific CD81
T lymphocytes in AIDS-NHL patients
To study the cause of the defective EBV-immune surveillance in
AIDS-NHL patients, we investigated both the number and function
of EBV-specific CD81 T cells in the course of HIV-1 infection in
AIDS-NHL patients. For comparison, progressors to AIDS-OI and
LTA individuals were studied. Detailed results from 2 study
participants (1 LTA, 1 AIDS-NHL) are shown in Figure 3. Most
EBV-specific CD81 T cells were directed against the lytic epitope
B8-RAK (0.7%-3.6% in Figure 3C), whereas fewer T cells were
directed against the latent epitope B8-FLR (0.1%-1.1% in Figure 3B). In
HLA-A21 individuals, 0.2% to 1.2% of the T cells were directed against
the lytic epitope A2-GLC (0.6%-0.8% in Figure 3D).
Figure 2. Percentage tetramer1 EBV-specific T cells and functionality of
tetramer1 T cells in HIV2 and HIV1 individuals. (A) The number of tetramer1
(percentage of CD81 T cells as assessed by tetramer staining) and (B) proportion of
IFN-g–producing T cells of tetramer1 T cells (percentage of tetramer1 T cells
determined after peptide stimulation) are shown for HIV2 (n 5 6, filled circles) and
HIV1 individuals (n 5 11) early in HIV infection (average of time points studied until
CD41 T cells drop below 200/mL or halfway through follow-up). HIV1 individuals
include individuals progressing to AIDS-NHL (n 5 5, open triangles) or AIDS-OI
(n 5 3, open circles) and LTA HIV-infected individuals (n 5 3, filled triangles).
Figure 3. Presence and function of lytic and latent EBV antigen-specific CD81 T
lymphocytes in an AIDS-NHL patient (left) and an LTA individual (right). On the
x-axis, follow-up is indicated in months after HIV-11 entry in the study. The arrows
indicate the time of NHL-diagnosis (NHL) and start of therapy (DDI). The vertical
dotted line indicates the time point at which CD41 T-cell counts drop below 200/mL.
(A) Longitudinal analysis of CD41 and CD81 T-lymphocyte numbers. (F) indicates
CD4; (E), CD8. (B) Longitudinal analysis of B8-FLR–specific CD81 T lymphocytes as
assessed by tetramer staining (percentage of CD81 T cells, solid line) and IFN-g
Elispot assay (per 106 CD81 T cells, dashed line). (F) indicates tetramer; (E), IFN-g.
(C) Longitudinal analysis of B8-RAK–specific CD81 T lymphocytes as assessed by
tetramer staining (solid line) and IFN-g Elispot assay (dashed line). (F) indicates
tetramer; (E), IFN-g. (D) Longitudinal analysis of A2-GLC–specific CD81 T lympho-
cytes as assessed by tetramer staining (solid line) and IFN-g Elispot assay (dashed
line), as described in “Patients, materials, and methods.” (F) indicates tetramer;
(E), IFN-g.
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For all individuals, the total percentage of tetramer1 and
number of IFN-g–producing (functional) EBV-specific CD81 T
cells was calculated from the individual peptide-specific CD81 T
cells. In Figure 4, average numbers of EBV-specific CD81 T cells
early and late in HIV-1 infection are shown for the 3 groups
studied. Figures 5 and 6 give detailed longitudinal information for
several of the investigated participants.
In most individuals no change in the percentage of tetramer1 T
cells was observed in the course of HIV-1 infection (Figure 4A). In
AIDS-NHL patients, the function of these EBV-specific T cells
significantly decreased in the course of HIV-1 infection (P 5 .04,
Wilcoxon test) (Figure 4B). The decrease in IFN-g–producing cells
(d IFN-g) tended to be stronger than the decrease in tetramer1 cells
(d tetramer1) corrected for the first time point (229% and 26%,
respectively, P 5 .07, Mann-Whitney test), indicating a discrep-
ancy in the kinetics of the number of EBV-specific T cells present
in comparison with their functionality.
The decrease in IFN-g–producing T cells was most pronounced
in patients NHL6006, NHL0308, and NHL0118, in whom almost
no IFN-g–producing CD81 T cells were left after a few years of
HIV-1 infection (NHL6006, left panel in Figure 5B,C; and
B8-FLR–specific T cells in NHL0308, Figure 2B) or near lym-
phoma diagnosis (NHL0118, middle panel in Figure 5B). This loss
of function was observed for both lytic and latent antigen-specific
responses (patient NHL0308, Figure 2B,C).
Furthermore, the decline in IFN-g–producing T cells, while the
number of tetramer1 T cells remained stable, leads to a loss of the
proportion of tetramer1 T cells that produced IFN-g in individuals
progressing to AIDS-NHL (Figure 4C). In contrast, in LTAs the
proportion of tetramer1 T cells that produced IFN-g even increased
in the course of HIV-1 infection. As a result, the decrease in IFN-g
(D IFN-g) in AIDS-NHL patients tended to be stronger than the
delta IFN-g in LTAs corrected for the first time point (229% and
13%, respectively, P 5 .07, Mann-Whitney test) (Figure 4C).
Progressors to AIDS-OI showed lower but stable percentages of
tetramer1 T cells (Figure 4A) and IFN-g–producing T cells specific
for EBV (Figure 4B), resulting in a stable proportion of IFN-g1/
tetramer1 T cells (Figure 4C). Interestingly, PROG0232, a slow
progressor to AIDS, showed an increase in the total number of
IFN-g–producing T cells just after the start of highly active
antiretroviral therapy (HAART) (Figure 6B).
Comparison of the number of IFN-g–producing T cells
determined by Elispot assay and intracellular staining
To confirm our findings with the Elispot assay, we also performed
intracellular IFN-g staining after peptide stimulation (B8-RAK) of
PBMCs from an AIDS-NHL patient at an early time point (Figure
7, left panel) and PBMCs from an LTA individual at 2 time points
(Figure 7, right panel). At an early time point in NHL0308, the
percentage of RAK-specific IFN-g–producing T cells as assessed
by intracellular staining (0.19%, or 1900 per 106 CD8) (Figure 7B)
is of the same magnitude as the number of IFN-g producers found
by Elispot assay (;1900, Figure 7A, dotted line). Similar to the
Elispot results, the number of CD81 T cells with intracellular
IFN-g staining increased in the course of infection for the LTA
individual (from 0.16% to 0.3%) after stimulation, which corre-
lated well with IFN-g production in Elispot (Figure 7A). Moreover,
the proportion of IFN-g–producing tetramer1 T cells for the
AIDS-NHL patient early in infection was 9% (Figure 7C), which
corresponded well with the percentages observed using tetramer
staining in combination with IFN-g Elispot assay (around 8% early
in HIV-1 infection) (Figure 4C).
EBV-specific CD81 T-lymphocyte function is dependent
on CD41 T cells
Next, we investigated whether there was a possible relation
between CD41 T-cell numbers and the number of EBV-specific
CD81 T cells. In AIDS-NHL patients, CD41 T-cell numbers
Figure 4. EBV-specific T cells and EBV load early and late in HIV-1 infection. For
3 groups of HIV-infected individuals, from the longitudinal data the average of early
(period studied until CD41 T cells drop below 200/mL or halfway through follow-up)
and late (average of time points from the drop in CD41 T cells below 200/mL or
halfway through follow-up until AIDS diagnosis or last time point studied) time points
in HIV-infection were calculated excluding time periods on therapy. For AIDS-NHL
patients (left), LTA individuals (middle), and AIDS-OI patients (right), the figure depicts
(A) the percentage of EBV tetramer1 CD81 T cells, (B) the number of IFN-g–
producing EBV-specific T cells per 106 CD81 T cells, (C) the proportion of IFN-g1
tetramer1 T cells, and (D) EBV load per 106 PBMCs.
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decreased significantly in the course of HIV-infection (P 5 .04,
Wilcoxon test). In 4 of 5 AIDS-NHL patients, loss of functional
EBV-specific CD81 T cells (Figure 5B,C) was related in time to a
drop in CD41 T-cell counts below 200/mL (Figure 5A). Further-
more, when CD41 T-cell counts increased again after antiretroviral
treatment (dideoxyinosine, or DDI) in patient NHL0308, a parallel
increase in functional EBV-specific CD81 T cells was observed
(Figures 3 and 5B).
In LTAs and progressors to AIDS-OI, who did not show a
functional loss of EBV-specific CD81 T cells (Figure 6B), CD41
T-cell numbers were stable during most time points and no significant
decrease in CD41 T-cell numbers was observed (P 5 .11, Wilcoxon
test). In LTAs and progressor P0232, CD41 T-cell numbers never
dropped below 200 CD41 T cells per microliter (Figure 6A).
Indeed, when CD41 T-cell numbers measured at all time points
were plotted against the number of EBV-specific CD81 T cells that
produced IFN-g, a correlation was found (b 5 0.076), which was
highly significant (P , .037), whereas no correlation was found
between CD41 T-cell numbers and the number of tetramer1 T cells
(b 5 20.043) (Figure 8). In addition, no correlation was found
between CD41 T-cell numbers and CD81 T-cell numbers, indicat-
ing that the correlation between CD41 T cells and the number of
functional EBV-specific T cells was not due to an increase in total
CD81 T cells (data not shown).
Functional loss of EBV-specific CD81 T lymphocytes is
paralleled by an increase in EBV load
To investigate whether loss of functional T cells is associated with
an increase in EBV load and whether this precedes the develop-
ment of AIDS-NHL, EBV load was determined using a sensitive
and specific real-time quantitative PCR. As shown in Figure 4, loss
of EBV-specific CD81 T-cell function (Figure 4B) was associated
with an increase in EBV load in AIDS-NHL patients (P 5 0.08,
Wilcoxon test) (Figure 4D), although the absolute number of EBV
copies was not different from absolute EBV load observed in LTAs
and other progressors to AIDS (D.v.B. et al, manuscript submitted).
Interestingly, in patient NHL0308 after the start of DDI treatment,
EBV-specific CD81 T cells slightly increased and a small reduction
in EBV load was observed (Figure 5C).
In contrast, in LTAs no increase and, in progressors to AIDS-OI,
even a decrease in EBV load was observed (Figure 4D, middle and
right panels). The increase in load (D load) in AIDS-NHL patients
was significantly different from the decrease in load (D load) in
LTAs (P 5 .05) and progressors to AIDS-OI (P 5 .03, Mann-
Whitney test) (Figure 4D). Interestingly, in LTAs occasional EBV
peak loads (Figure 6C) were paralleled by an increase in the
number of functional EBV-specific CD81 T cells (Figure 6B) after
which EBV load decreased, suggestive of EBV control. HAART,
which led to an increase in the number of IFN-g–producing CD81
T cells (Figure 6B), resulted in a decrease of EBV load in
progressor PROG0232 (Figure 6C).
To study whether EBV load is able to drive the number of
IFN-g–producing T cells, we performed multivariate analysis
including the number of CD41 T cells, EBV load, and the number
of IFN-g–producing T cells. Although multivariate analysis of all
HIV-infected individuals (n 5 11) showed that only the number of
CD41 T cells could predict the number of functional cells
(b 5 0.92, P 5 .0188), analysis of only AIDS-OI patients and
Figure 5. Presence and function of EBV-specific
CD81 T cells and EBV load in 3 HIV-1 infected
individuals with AIDS-NHL. On the x-axis follow-up is
indicated in months after HIV-11 entry in the study. The
arrows indicate the time of AIDS-NHL diagnosis (NHL)
and start of antiretroviral therapy (DDI). The vertical
dotted line indicates the time point at which CD41 T cell
counts drop below 200/mL. (A) Longitudinal analysis of
CD41 and CD81 T-lymphocyte numbers. (F) indicates
CD4; (E), CD8. (B) Longitudinal analysis of EBV-specific
CD81 T lymphocytes as assessed by tetramer staining
as a composite of all tested tetramers (solid line) and
IFN-g Elispot assay (dashed line), as described in “Pa-
tients, materials, and methods.” (F) indicates tetramer;
(E), IFN-g. (C). Longitudinal analysis of EBV load, ex-
pressed as the number of virus copies per 106 PBMCs
(solid line), in comparison with the number of functional
EBV-specific CD81 T lymphocytes per 106 CD81 T cells
(dashed line). (F) indicates EBV load; (E), IFN-g.
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LTAs (n 5 6) showed that both EBV load (b 5 0.16, P 5 .001)
and the number of CD41 T cells (b 5 0.89, P 5 .0022) could
predict the number of functional T cells. This suggests that EBV
load is indeed able to drive EBV-specific T cells when sufficient
CD41 T cells are present.
Discussion
To investigate the cause of decreasing numbers of CTLp in
AIDS-NHL patients, which is believed to lead to defective
EBV-immune control, we studied number (using MHC class I
tetramers) and function (using IFN-g Elispot assay) of EBV-
specific CD81 T lymphocytes in the course of HIV infection in
relation to EBV load. This is, to our knowledge, the first longitudi-
nal study demonstrating a discrepancy between direct visualization
using tetramer staining and functional assays enumerating IFN-g–
producing antigen-specific T cells. The major conclusions from our
study are that (1) HIV1 individuals have lower numbers of
functional EBV-specific CD81 T cells than HIV2 individuals;
(2) in AIDS-NHL patients, EBV-specific CD81 T cells are lost
preferentially at the functional level and are not physically lost;
(3) loss of EBV-specific CD81 T-cell function is correlated with
lower CD41 T-cell numbers; (4) increasing EBV load correlates
with loss of EBV-specific immunity; and (5) the number of T cells
directed against lytic antigens is higher than against latent antigens.
The observed correlation between loss of function of EBV-
specific CD81 T cells and lower CD41 T-cell numbers indicates an
important role for CD41 T cells in maintaining the functional
capacity of CD81 T cells. Our data are in good agreement with
studies on T-helper dependence of chronic lymphocytic choriomen-
ingitis virus (LCMV)-specific CTL in mouse models.25-27 A critical
role for CD41 T cells has also been shown during immunization,28
and progressive loss of CTL in the absence of adequate helper cell
function has been demonstrated for several murine viral infec-
tions.29-31 Furthermore, CD41 T cells also appear to be essential for
long-term persistence of adoptively transferred virus-specific CTL
in humans.27,32,33
In the natural course of HIV infection, it has been shown that
progressors to AIDS lose CD81 CTLs when functional HIV-
specific CD41 T cells disappear. In contrast, in nonprogressors,
who have stable CD41 T-cell numbers, HIV-specific CTL re-
sponses can be sustained for long periods of time,34-37 indicating
that sustained HIV-specific helper activity is required for mainte-
nance of functional CD81 T-cell responses.34,38,39
The fact that most EBV-specific CD81 T cells were directed
against lytic epitopes suggests that these lytic antigen-specific T
cells play a role not only during acute infection40 but also in
controlling EBV reactivation by eliminating virus-producing cells
at an early stage. Loss of functional lytic antigen-specific CD81 T
cells could therefore lead to an increase in EBV DNA, as we indeed
observed. As the pool of EBV-infected B cells grows, there is an
increased risk of subsequent genetic hits resulting in malignant
outgrowth of EBV-infected B cells. Because functional CD81 T
cells specific for latent antigens appear to be lost as well, newly
developed tumor cells will not be destroyed. Our data suggest that
loss of both lytic and latent antigen-specific CD81 T cells may
contribute to the risk for development of AIDS-NHL.
In HIV infection, 0.2% to 5% of the CD81 T cells were found to
be EBV-specific, of which 13% were shown to produce IFN-g in
response to EBV peptides. This is lower than in healthy HIV2 EBV
carriers, where the percentage of IFN-g–producing T cells was
approximately 22% (our data), consistent with data from litera-
ture.41 In AIDS-NHL patients, the number of IFN-g–producing T
cells was found to decrease progressively in the course of HIV
infection, resulting in a much lower percentage of IFN-g–
Figure 6. Presence and function of EBV-specific
CD81 T cells and EBV load in 2 HIV-1 infected LTA
individuals and 1 HIV-1 infected individual progress-
ing to AIDS-OI. On the x-axis, follow-up is indicated in
months after HIV-11 entry in the study. The arrows
indicate the time of AIDS diagnosis (OI) and start of
HAART. (A) Longitudinal analysis of CD41 and CD81
T-lymphocyte numbers. (F) indicates CD4; (E), CD8.
(B) Longitudinal analysis of EBV-specific CD81 T lympho-
cytes as assessed by tetramer staining as a composite of
all tested tetramers (solid line) and IFN-g Elispot assay
(dashed line), as described in “Patients, materials, and
methods.” (F) indicates tetramer; (E), IFN-g. (C) Longitu-
dinal analysis of EBV load, expressed as the number of
virus copies per 106 PBMCs (solid line), in comparison
with the number of functional EBV-specific CD81 T
lymphocytes per 106 CD81 T cells (dashed line).
(F) indicates EBV load; (E), IFN-g.
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producing T cells in the tetramer1 T-cell population. Therefore, our
data indicate that, next to tetramer staining, functional analysis of
antigen-specific T cells may be required to fully appreciate the role
of CD81 T cells in various clinical conditions. The observed
discrepancy between number and function of EBV-specific CD81
T cells is underscored by the finding that CD41 T-cell numbers
correlated with the number of IFN-g–producing EBV-specific
CD81 T cells but not with the number of tetramer1 CD81 T cells.
The observed low percentage of IFN-g–producing T cells is not
likely to be a consequence of susceptibility to rapid activation-
induced cell death in vitro, caused by preactivation in vivo.
Because tetramer staining results before and after stimulation are
virtually the same (data not shown), this indicates that antigen-
specific cells are not lost after stimulation. In addition, when dead
cells are included in the analysis no increase in the percentage of
tetramer1 T cells was observed, suggesting that even if cells are
lost, this is not occurring selectively in the EBV-specific CD81 T
cells. Furthermore, we studied expression of CD69, which has been
shown to be highly expressed on nonresponsive T cells in
LCMV-infected CD4 knockout mice.27 However, expression of
CD69 on EBV-specific CD81 T cells was low, reaching no higher
levels than 5% of the tetramer1 T cells (data not shown). Indeed, it
has been shown that, compared with healthy individuals, a higher
percentage of PBMCs from HIV-infected individuals undergo
apoptosis after overnight stimulation.42 However, death of T cells
was not correlated with CD41 T-cell numbers or T-cell function and
was not confined to expression of T-cell activation markers.43
Moreover, it has been shown that virus-specific CD81 T cells are
able to rapidly reinitiate cytokine production after recent stimula-
tion.44 Thus, even if the EBV-specific T cells are recently activated
or preactivated in vivo, this should result in a rapid production of
IFN-g. Overall, these observations make considerable in vitro
death of EBV-specific T cells unlikely.
The low percentage of IFN-g–producing T cells was also not
due to a suboptimal assay condition, because the Elispot assay was
shown to detect virtually all antigen-specific T cells when a T-cell
clone was analyzed. Furthermore, the percentage IFN-g–producing
T cells as assessed by intracellular staining was similar to the
percentage of IFN-g producers found by Elispot assay in both
healthy controls (data not shown) and patients (Figure 7).
The phenomenon of antigen-specific CD81 T cell dysfunction
has also recently been shown for hepatitis C virus45 during a period
of acute infection, for tumor-specific T cells in melanoma pa-
tients,46 and for HIV-specific T cells.47 This state of dysfunction has
been shown to occur both at the level of IFN-g production and
cytolytic activity.45,46 In addition, in healthy individuals there is a
correlation between IFN-g–producing T cells and CTLp frequen-
cies.41 Furthermore, our own observations indicate that the number
of CTLp8 and IFN-g–producing T cells correlate, and both
decreased in the course of HIV-infection in AIDS-NHL patients.
In AIDS-NHL patients the observed loss of function of EBV-
specific CD81 T cells was accompanied by an increase in EBV
load, although absolute EBV load did not differ between groups
(data not shown). This increase in EBV load cannot be attributed to
technical variation, because we have low variation in duplicate
measurements (7.5%) and correction for the quantity of input DNA
did not change the observed patterns. In addition, increases in EBV
load are not due to increases in the number of total B cells, because
correction for the number of B cells in PBMC samples did not lead
to altered patterns (data not shown).
Thus, finally, in AIDS-NHL patients immune control over EBV
Figure 7. Correlation of IFN-g–producing T cells by Elispot and intracellular
FACS-staining. (A) Number of tetramer1 (percentage of CD81 T cells, solid line) and
IFN-g–producing T cells (per 106 CD81 T cells, dashed line), as assessed by Elispot
assay, are shown in the course of HIV-1 infection for RAK-specific T cells of one
AIDS-NHL patient (NHL0308, left panel) and one LTA individual (LTA0036, right
panel). (F) indicates tetramer; (E), IFN-g. (B) Intracellular IFN-g staining, as
described in “Patients, materials, and methods,” after stimulation with RAK peptide is
shown at an early time point in HIV-1 infection for the AIDS-NHL patient and an early
and late time point for the LTA individual, revealing the percentage of IFN-g–
producing CD81 T cells (upper right quadrant). (C) Combination of tetramer and
intracellular IFN-g staining after peptide stimulation is shown at an early time point for
the AIDS-NHL patient, revealing the percentage tetramer1 (2.3%, upper left quad-
rant) T cells, IFN-g1 (0.21%, upper and lower right quadrant) T cells, and proportion of
IFN-g1 tetramer1 CD81 T cells (9%, gray box).
Figure 8. Correlation of CD41 T-cell numbers with functional EBV-specific CD81
T cells. CD41 T-cell numbers (cube root transformed) of all time points of the 11
HIV-1–infected individuals are shown, determined as described in “Patients, materi-
als, and methods,” against (A) total number of functional EBV-specific CD81 T cells
per 106 T cells (cube root transformed), determined by IFN-g Elispot assay as
described in “Patients, materials, and methods,” and (B) the cumulative percentage
EBV-tetramer1 CD81 T cells (cube root transformed), assessed by staining PBMCs
with HLA–EBV-peptide tetrameric complexes as described in “Patients, materials,
and methods.” (F) indicates AIDS-NHL; (E), LTA; and (), AIDS-OI.
DYSFUNCTIONAL EBV-SPECIFIC T CELLS IN AIDS-NHL 153BLOOD, 1 JULY 2001 z VOLUME 98, NUMBER 1
seemed to be lost. Surprisingly, in LTAs enormous transient bursts
of EBV load were observed. These peaks in viral load seemed to be
paralleled by expansions of functional CD81 T cells specific for
EBV. Because EBV load subsequently decreased, these cells
apparently were able to control EBV viremia. Indeed, multivariate
analysis of AIDS-OI patients and LTAs showed that EBV load,
besides the number of CD41 T cells, could predict the number of
functional T cells, indicating that EBV load is indeed able to drive
EBV-specific T cells when sufficient CD41 T cells are present.
In progressors to AIDS-OI, EBV-specific CD81 T cells on total
were lower, suggestive of physical loss or lack of expansion of
these T cells. In these patients, the relatively low number of
EBV-specific T cells did, however, not lead to an increase in EBV
load, suggesting that there is adequate control. Alternatively, it
could be that these individuals eventually would have developed
AIDS-NHL had they not developed AIDS-OI.
In conclusion, our data suggest that the development of
AIDS-NHL is a multifactorial process involving at least virologic
and immunologic parameters. Thus, both determinants are required
to obtain a complete picture of the virus-host balance. We show that
not so much the total number of circulating EBV-specific CD81 T
cells but, mainly, the number of functional EBV-specific CD81 T
cells is important in keeping EBV infection under control. When
EBV-specific CD81 T cells start to lose function, in most cases as a
consequence of a decrease in CD41 T cells, this is paralleled by an
increase in EBV load. To be able to predict the occurrence of an
AIDS-NHL, all these factors should be taken into account.
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